Image Place holder

Andrew T. Kuykendall, MD


Specialty: Hematology/Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Leukemia , Myelodysplastic Syndromes (MDS)

Dr. Kuykendall is an Assistant Member at Moffitt Cancer Center in the Department of Malignant Hematology. He earned his MD from the University of Florida College of Medicine and completed an Internal Medicine Residency at the University of South Florida. Dr. Kuykendall completed a Hematology and Medical Oncology Fellowship at Moffitt Cancer Center/University of South Florida, Morsani College of Medicine, where he also served as Chief Fellow. His primary clinical and research interests are within the field of myeloproliferative neoplasms, for which he will build upon the molecular understanding of these diseases to identify rational therapeutic targets and develop personalized clinical trials. Dr. Kuykendall will also play an active role in the clinical care of all patients with myeloid malignancies.

Education & Training

Board Certification:

  • Internal Medicine

Fellowship:

  • University of South Florida at Moffitt Cancer Center - Hematology and Medical Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • University of Florida College of Medicine - M.D.
Participating Trials

CLINICAL TRIAL 19659
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Condition: Malignant Hematology
Intervention: INCB053914; Jakafi (Ruxolitinib); Ruxolitinib
Open

CLINICAL TRIAL 19379
A Phase 2, Multicenter, Open-Label Study To Evaluate The Efficacy And Safety Of Luspatercept (Ace-536) In Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis And Anemia With And Without Red Blood Cell-Transfusion Dependence
Condition: Malignant Hematology
Intervention: ACE-536 (Luspatercept); Luspatercept
Open

CLINICAL TRIAL 19429
A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis
Condition: Malignant Hematology
Intervention: ABT-263 (Navitoclax); Jakafi (Ruxolitinib); Navitoclax; Ruxolitinib
Open

CLINICAL TRIAL 19737
S1712, " A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease.- Study Chairs: Kendra Sweet, M.D., Jerald P. Radich, M.D.
Condition: Malignant Hematology
Intervention: AMN107 (Nilotinib); Dasatinib (BMS-354825); Jakafi (Ruxolitinib); Nilotinib; Ruxolitinib; Tasigna (Nilotinib)
Open

CLINICAL TRIAL 19825
A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes
Condition: Malignant Hematology
Intervention: APR-246; azacitidine (5-azacitidine)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Talati C, Dhulipala VC, Extermann M, Al Ali N, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE. Comparisons of commonly used frontline regimens on survival outcomes in patients age 70 years and older with acute myeloid leukemia. Haematologica. 2019 May. Pubmedid: 31073071.
  • Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Malloy M, Castro-Malaspina H, Giralt S, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biol Blood Marrow Tr. 2019 Jun;25(6):1142-1151. Pubmedid: 30625392.
  • Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan;94(1):87-92. Pubmedid: 30390311.
  • Kuykendall A, Duployez N, Boissel N, Lancet JE, Welch JS. Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. Am Soc Clin Oncol Educ Book. 2018 May;38:555-573. Pubmedid: 30231330.
  • Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar;97(3):435-441. Pubmedid: 29189896.
  • Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. Pubmedid: 28869184.
  • Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 03;129(13):1881-1883. Pubmedid: 28159734.
  • Kuykendall A, Chiappori A. Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations. Cancer Control. 2014 Jan;21(1):67-73. Pubmedid: 24357744.